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[57] ABSTRACT 
A composition which has potent anti-HIV activity. The 
composition is a high energy coprecipitate of nonoxynol-9 
oligomers, polyvinyl-pyrrolidone (PVP) and iodine or 
PVP~I and shows a pronounced synergistic, anti-HIV effect 
between the compounds of the composition. The invention 
also includes paper and plastic products coated with the 
composition of the invention. 
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COATED PRODUCTS WITH POTENT 
ANTI-HIV AND ANTIMICROBIAL 
PROPERTIES 
This application is a continuation in part application of 
U.S. Ser. No. 08/106,948 ?led Aug. 17, 1993, now U.S. Pat. 
No. 5,380,523. 
TECHNICAL FIELD 
I. The present invention relates to a composition with 
potent anti-HIV activity. The composition is a high energy 
coprecipitate of nonoxynol oligomers, polyvinylpyrrolidone 
(PVP) and iodine and shows a pronounced synergistic e?ect 
between the compounds of the composition. 
II. The invention also relates to products coated with the 
high-energy coprecipitate composition, particularly to 
coated paper products, including surgical gowns and hospi 
tal linens. 
III. The invention additionally relates to products coated 
with the high-energy coprecipitate composition, particularly 
to plastic products, including surgical gloves and prophy» 
lactics. 
BACKGROUND 
Nonoxynol or nonylphenol(polyethoxy)ethanol is a non 
ionic surfactant used as the active ingredient in the majority 
of the commercially available spermicides. It inhibits the in 
vitro growth of venereal pathogens (see Benes, S. et al., 
(1985) Antimicrob. Agent Chemothen 27: 724-726; Kelly, J. 
P. et al., (2985), Antimicrob. Agent Chemother 27: 760-762; 
Austin, H., et al., (2984) JAMA, 251: 2822-2824; and Singh, 
B. et al., (1972) Br: J. Vener. Dis. 48: 57-64), including the 
herpes simplex viruses (see Asculai, S. S. et al., (1978) 
Antimicrob. Agent Chemother: 13: 686-690; Hicks, D. R., 
(1985) Lancet, 1422-1423; Friedman-Kein, (1986) J. Am. 
Acad. Dermal. 15: 989-994; Rapp, R. et al., (1985) Anti 
microb. Agent Chemother. 28: 449-451; Voeller, B., (1986) 
Lancet, 1153; Malkovsky, M. et al., (1988) Lancet, 645; and 
Barbi, M. et al., (1987) Ball. 1st. Sieroter. (Milan) 66: 
158-160). 
By the nature of its synthesis, the nonoxynol-9 (N-9) 
(Igepal CO-630) derivative of nonoxynol is a polymer 
consisting of at least 17 oligomers of varying ethylene oxide 
(E0) chain length. The molecule of N-9 contains a hydro 
phobic moiety (nonylphenol portion) and a hydrophilic 
chain composed basically of ethylene oxide units. The 
compound is a product of a statistical polymerization reac 
tion of 9 moles of ethylene oxide and one mole of non 
ylphenol (see equation below): 
0 
Na“ \ 
CgHrg on + rrzc CH1 % 
Nonoxynol-9 (N-9) 
where “n” represents the number of ethylene oxide units. 
The above reaction does not yield a distinct compound but 
a mixture of oligomers with different molecular weights. 
The physical and chemical characteristics of these oligomers 
change as a function of the varying molecular weight. (See 
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Liebert, M. A., (1983) J. Am. Coll. Toxicol. 2: 35-60). As the 
length of the E0 chain increases, the oligomers increase in 
water solubility. Nonoxynol-9 oligomers 1 through 6 (n=1— 
6) are considered oil soluble compounds, whereas the oli 
gomers with a longer EO chain are soluble in water and 
polar organic solvents (see Liebert, supra). 
These di?erences in chemical properties of N9 oligomers 
aifect their biological behavior both in vitro and in vivo. For 
instance, it was noted that the dermal toxicity of nonoxynol‘ 
decreases as the molecular weight increases (see Liebert, 
supra) and that smaller molecular weight nonoxynol may be 
more toxic to ?broblasts than the larger ones (see Chvapil, 
M. et al., (1980) Fertil. Steril. 33: 521-525). 
The in vitro sperrnicidal activity of the N-9 surfactant is 
also related to its molecular weight. Thus the oligomer n=9 
when separated from the N9 compound, was much more 
effective in inhibiting the motility of the spermatozoa than 
the higher molecular weight nonoxynols where n=30, 50, 
and 100. (See Chvapil, M. et al., (1980) Fertil. Steril. 33: 
521-525.) The lower molecular weight nonoxynols (n=1 or 
4) could not be studied appropriately because of their poor 
solubility in the aqueous testing medium (see Chvapil, 
supra). 
Analogous dependence on molecular weight was 
observed in vivo. Oral absorption studies in the rat indicated 
that increasing the length of the ethylene oxide chain 
decreased N-9 oligomer intestinal absorption (see Knaak, J. 
B. et al., (1966) Toxicol. Appl. Pharmacol. 9: 331-340). 
Furthermore, data showed that absorption of N9 through 
the vaginal membrane was poor and re?ects the preferential 
absorption of lyophilic low molecular weight oligomers. 
(See Walter, B. A. et al. (1988) Toxicol. Applied Pharmacol. 
96: 258-268.) 
An e?icient high pressure liquid chromatography (HPLC) 
method for the separation of [14C] N9 and characterization 
of the oligomeric components of the spermicide N~9 has 
been developed. (See Walter, B. A. et al. (1988) Toxicol. 
Applied Pharmacol. 96: 258-268; and Walter, B. A. et al., 
(1991) Pharm. Res. 8: 409-411). 
Utilizing this normal phase gradient elution HPLC 
method, at least seventeen oligomers were isolated from 
commercial N-9. Selected oligomers representing the high, 
medium and low molecular weight fraction of N-9 were 
separated in milligram quantities by normal phase gradient 
HPLC (see Walter, B. A. et al., (1991) Pharm. Res. 8: 
409-41'1; and Walter, B. A. et al., (1991) Pharm. Res. 8: 
403-408). 
Polyvinylpyrrolidone (also known as povidone USP) is 
one of the most highly utilized polymers in medicine 
because of its safety for human use and unique hydrophilic 
properties (see Robinson, B. V. et al. (1990), A critical 
review of the Kinetics and Toxicology of Polyvinyl-pyrroli 
done, Lewis Publishers, Inc., Michigan). 
Discovered and used during World War II as a plasma 
expander, PVP is currently used as excipient in many 
pharmaceutical preparations intended for external use (e.g. 
povidone-iodine USP solutions such as Betadine); for oral 
use, such as a solubilizing agent and tablet disintegrant, and 
for vaginal use such as in PVP-I douche. 
Several studies have focused on the dissolution rate 
behavior of drug-povidone coprecipitates. (See Higuchi, W. 
I. et al., (1983) in Proceedings of the International Sympo 
sium on Povidone, Digenis, G. A. and Ansell, J., Eds. 
Lexington, pp. 71-79; Simonelli, A. P. et al., (1987) in 
Proceedings of the 2nd International Symposium on Povi 
done, Digenis, G. A. and Agha, B. J., Eds., Lexington, pp. 
392-401; Simonelli et al., (1969) J. Pharm. Sci, 58: 
538-549; Simonelli et al. (1976) ibid. 65: 355-361.) 
5,492,692 
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These studies found that the preferential dissolution of 
one component (hydrophilic polymer, such as PVP) can 
enhance the dissolution of the other component in a copre 
cipitate. 
Drug/PVP high energy coprecipitates can be described as 
a drug incorporated into a solid PVP solution. Drug release 
from PVP coprecipitates are shown to follow dissolution 
kinetics of the polymer carrier of PVP provided that the PVP 
solvent uptake or swelling proceeds freely without inhibition 
by the drug. 
Mayersohn and Gibaldi (Mayersohn M. et al., (1966) J. 
Pharm. Sci. 55: 1323-1324) showed greatly enhanced dis 
solution of the antibiotic griseofulvin when the drug was 
coprecipitated with povidone (PVP). Higuchi et al. investi 
gated a povidone/sulfathiazole system and suggested that the 
resultant enhanced aqueous solubility of sulfathiazole was 
due to a high energy state of the drug in the PVP coprecipi 
tate resulting in a supersaturated form of the drug after 
introduction into aqueous media. (See Higuchi, W. I. et al., 
(1983) in Proceedings of the International Symposium on 
Povidone, Digenis, G. A. and Ansell, J., Eds. Lexington, pp. 
71-79.) 
Simonelli et al., envisioned a PVP/drug coprecipitate 
model consisting of two components including the drug in 
amorphous state and PVP. (Simonelli, A.P. et al., (1987) in 
Proceedings of the 2nd International Symposium on Povi 
done, Digenis, G. A. and Agha, B. J., Eds., Lexington, pp. 
392-401; Simonelli et al., (1969) J. Pharm. Sci. 58: 
538-549; Simonelli et al. (1976) ibid. 65: 355-361.) 
The in vitro spermicidal activity of three molecular 
weight fractions of N -9 were compared to that of N-9, using 
rabbit spermatozoa, at equimolar concentrations. nonox 
ynol-9/PVP complexes were found to be far more effective 
in immobilizing the sperm than either N-9 alone or in the 
separate fractions (Walter, B. A. et al., (1991) Pharm. Res. 
8: 403-408). 
The spermicidal activities of three oligomeric fractions of 
N-9 with human sperm have been assessed. Equimolar 
concentrations of three different molecular weight fractions 
of N-9 coprecipitated with PVP were used. These equimolar 
concentrations were 166 ug/ml for high molecular weight 
(HMW), (MW=599), 123 pg/ml for middle molecular 
weight (MMW) (MWI499) and 85 uglml for low molecular 
weight (LMW) (MW=306) N-9 fractions. The order of 
e?icacy in immobilizing the human spermatozoa was 
HMW(MW=599)>MMW(MW:499)>LMW(MW:306) 
with complete sperm immobilization observed with PVP 
coprecipitated with N-9 HMW within 4.0 minutes and PVP 
coprecipitated with N9 MMW within 15 minutes after 
exposure. Furthermore, addition of the spermicides inter 
fered with the progressive motility and linearity of the sperm 
swimming pattern. PVP and buifer controls showed no 
decline in percentage motility over the course of the test. 
Chvapil et al. recognized that the n? oligomeric fraction 
of nonoxynol-9 was more etfective in inhibiting the motility 
of spermatozoa than the higher molecular weight nonox 
ynols. Chvapil et al., however, were unable to study the 
lower molecular weight oligomers (n=l-4) because of their 
poor solubility in aqueous media. 
In contrast, however, Walter et a1. were able to solubilize 
the water insoluble lower molecular weight N-9 oligomers 
by complexing them with the hydrophilic polymer polyvi 
nylpyrrolidone (PVP). (See Walter, B. A. et al., (1991) 
Pharm. Res. 8: 403-408.) 
The resulting high energy coprecipitate complexes of the 
low molecular species of N-9 were found to be at least 
eifective spermicides at all concentrations tested when com 
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pared to their counterparts that were prepared from higher 
molecular weight N-9 oligomeric fractions. However, they 
were themselves elfective spermicides. The above ?ndings 
concluded that when N-9 is coprecipitated with PVP its 
spermicidal activity is enhanced. While PVP alone has no 
inherent sperm toxicity, the formation of N-9/PVP com 
plexes seem to produce a synergistic response which causes 
a more rapid damage to the sperm than any of the two 
materials alone (Walter, B. A. et al., (1991) Pharm. Res. 8: 
403-408). 
Nonoxynol-9 (N-9) has been shownto be useful in the 
prophylaxis against sexually transmitted diseases (STD). 
(See Bird, K. D., (1991) AIDS 5: 791-796; and Louv, W. C. 
et al., (1988) J. Infect. Dis. 158: 518-523). 
More recently, this spermicide has been shown to be 
effective against cell-associated HIV at concentrations of 
20.05% (v/v). (See Hicks, D. R. et al., (1985) Lancet, ii: 
1422-1423; Vopeller, B., (1986) Lancet, i: 1153; and Malk» 
ovsky, M., Newell, A., Dalgleish, A. G., (1988) lancer, i: 
645). 
Unfortunately, N-9 causes epithelial disruption of the 
cervix and vagina when administered in high doses and high 
frequency (see Niruthisard S. et al., (1991) Sex. Transm. Dis. 
18: 176-179). Higher rates of new IHV infections were 
found in prostitutes who used N-9 at great frequencies (see 
Kreiss, J. et al., International Conference on AIDS, Mont 
real, June 1989 [Abstract MAO36]). This observation was 
attributed to the high incidence of genital ulceration caused 
by high doses of N-9, in this group of women. Thus, the 
above ?ndings tend to suggest that novel spermicide for— 
mulations containing N-9 should be e?icacious at the small 
est possible doses so that the integrity of the vaginal epi 
thelium is not compromised. 
The antimicrobial properties of povidone-iodine (PVP-I), 
a complex of polyvinyl pyrrolidone and iodine, have been 
well documented. PVP-I solutions (10% w/v) USP are 
among the most widely utilized antimicrobial agents. A 10% 
(w/v) solution of PVP-I contains 1% (w/v) of available 
iodine (12). The microbiological potency of PVP-I arises 
from the elemental (diatomic) or free iodine (I2) in solution. 
The signi?cant characteristic of iodophors, such as PVP-I, is 
that they carry almost all of their iodine in a complexed 
forrnso that the amount of free iodine (I2) is quite low and 
PVP-I serves as the iodine reservoir delivering the free 
iodine into the solutions. Thus, iodophors exhibit reduced 
irritation properties and are relatively non-toxic (see 
LaRocca, R. et al., (1983) in Proceedings of the International 
Symposium on Povidone, Digenis, G. A. and Ansell, J., Eds. 
Lexington, pp. 101-119). 
Stable, sterile (0.2%) PVP-I compositions containing as 
little as 0.02% iodine have been shownto be useful in 
treating eye infections in humans. A level of 0.02% iodine 
obtained by diluting a commercial 10% PVP-I solution at 
1:50 with saline solution, is generally considered to be 
optimum to maximize performance and rninirrrize irritation 
(see Winicov, M. et al., (1987) in Proceedings of the 
International Symposium on Povidone, Digenis, G. A. and 
Ansell, J ., Eds. Lexington, pp. 57-64). 
Data has shown that with doubly labeled 1“C-PVP-T-“I 
solutions the amount of iodine delivered into gram positive 
and negative bacteria cultures was three times greater when 
the iodine was complexed with PVP, than from an equimolar 
solution of 131I3- (Lugol’s solution). (See Digenis, G. A. et 
al., (1983) in Proceedings of International Symposium on 
Povidone, Digenis, G. A. and Ansell, J., Eds. Lexington, pp. 
302-311). 
The hydrophilic polymer PVP acts as a delivery system 
for iodine probably due to the membrane seeking properties 
5,492,692 
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of this polymer. Ben-David and Gavendo have shown that 
PVP at 4.6% w/v concentrations protect red blood cells from 
osmotic fragility and mechanical injury. (See Ben-David A. 
et al., (1972) Cryobiology, 9: l92—197). These workers 
suggested that this effect is brought about by a “coating” or 
external interaction of PVP with cell membranes. 
The membrane-seeking properties of PVP suggest that in 
addition to its contribution to the solubilization ability of 
N-9, the PVP polymer, via its cell—membrane coating prop‘ 
erties, also provides vaginal and cervical surface coverage 
coating with N9 and iodine over extended periods of time. 
In addition to its antimicrobial properties, PVP-I has been 
shown to inactivate HIV. (See Kaplan, J. C. et al. (1987) 
Infect. Control 8: 412-424; and Harbison, M. A. et al., 
(1989) J. Acquir. Immune De?c. Syndr: 2: 16-20). The 
concentration of iodine used in Kaplan’s studies was equal 
to 0.025% for 250 ppm of I2. 
A 0.02% w/v (200 ppm) solution of iodine is considered 
non-toxic and non-irritating and is used for treatment of eye 
infections in humans. (See Winicov, M. et al., (1987) in 
Proceedings of the International Symposium on Povidone, 
Digenis, G. A. and Ansell, J., Eds. Lexington, pp. 57—64). In 
fact, the increased bactericidal activity of dilute solutions of 
povidoneiodine (Betadine - 10% w/v PVP'I) have recently 
been well documented. Betadine contains 10,000 ppm (or 
10,000 pg/ml) of available iodine and is often irritating to 
the tissues and has an undesirable brown color. (See Ber 
kelman, R. L. et al., (1982) J. Clin. Microbiol. 15: 635-639.) 
At concentrations of about 0.02% w/v of iodine, the unde 
sirable brown color of iodine is not a problem since in dilute 
solutions the color is hardly seen and the amount of iodine 
is not irritating to tissues. 
None of the prior research in this area recognized the 
synergistic anti-HIV result of all three compounds when 
formulated into a high energy coprecipitate. 
Furthermore, spermicides containing nonoxynol-9 and 
polyvinylpyrrolidone or polyurethane are known. 
U.S. Pat. No. 4,317,447 to Williams discloses a device for 
delivering a medicament to the vaginal cavity consisting of 
a molded sheath of a mixture of a polymeric material and a 
medicament. The medicament which is dispersed in the 
polymeric material can be nonoxynol-9. The polymer may 
be selected from modi?ed cellulose, polyvinyl alcohol, 
polyvinylpyrrolidone, polyacrylic and ethylene oxide poly 
mer. Williams does not disclose the use of PVP-I in com 
bination with a nonoxynol-9. 
U.S. Pat. No. 5,156,164 to LeVeen et al. discloses that 
iodine can be dissolved in alcohol containing nonoxynol in 
a complex with polyurethane. LeVeen et al. disclose that a 
polyvinylpyrrolidone~iodine complex has been eifective in 
treating resistant vaginitis. LeVeen et a1. do not disclose or 
suggest combining PVP-I with nonoxynol. 
U.S. Pat. No. 5,070,889 to Leveen et al. discloses a 
contraceptive sponge and tampon made of polyurethane 
iodine complex. Leveen et al. teaches away from the use of 
povidone iodine or use as a contraceptive. 
U.S. Pat. No. 5,073,365 to Katz et al. discloses clinical 
and personal care articles enhanced by lubricants and adju 
vants. The devices can bev made of polyvinylpyrrolidone or 
polyurethane interpolymers. The device may take the form 
of vaginal diaphragms, tampons, condoms or cervical caps. 
The medicament may be nonoxynol-9. Katz et al. disclose 
that the personal care articles may prevent the transmission 
of venereal diseases, possibly including AIDS. 
U.S. Pat. No. 4,707,362 to Nuwayser discloses a sustained 
release composition made of synthetic polymers such as 
polyvinylpyrrolidone. The bioerodible material in one 
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embodiment has been modi?ed so that a spermicide such as 
nonoxynol-9 is slowly released. Nuwayser does not disclose 
PVP-I in combination with nonoxynol-9. 
U.S. Pat. No. 4,954,351 to Sackler et al. discloses a 
method of producing standardized povidoneiodine prepara 
tions. The patent discloses that the povidone-iodine solution 
can be incorporated into a suppository with 0.1 to 10% by 
weight of povidone-iodine. Sackler et al. do not disclose the 
use of povidoneiodine in combination with nonoxynol-9. 
U.S. Pat. No. 4,297,341 to Waller et al. discloses that a 
water-soluble complex comprising polyvinylpyrrolidone 
and gossypol is an effective spermicide. The patent discloses 
that a PVP-gossypol combination when compared to a 
comparative example of nonoxynol-9 alone, exhibited equal 
or greater spermicidal properties. Waller does not disclose 
PVP-I in combination with nonoxynol~9. 
U.S. Pat. No. 4,925,033 to Stoner et al. discloses a 
rnicrobicidal cleanser/barrier kit. One method of the inven 
tion involves applying a solution of povidone-iodine (PVP 
I) to vaginal sponges or condoms. In another embodiment 
the povidone-iodine active ingredient may be added to 
spermicidal birth control compounds. Stoner et al. disclose 
that nonoxynol-9 is a known spermicidal compound. Stoner 
et a1. do not disclose or suggest the particular combination 
of components in the form of a high energy coprecipitate, 
nor that the compounds show a synergistic anti-HIV effect. 
Heterosexual transmission of human immunode?ciency 
virus (HIV), the causative agent of AIDS, is a growing 
concern in the United States where 37% of AIDS cases are 
heterosexually transmitted, the majority being male-tofe 
male. Moreover, the frequency of global heterosexual trans 
mission is probably greater where it is estimated to exceed 
60% of all AIDS cases. 
It has been suggested that a major contributing factor to 
heterosexual transmission of HIV is the presence of cell-free 
virus and virus-infected cell (cell-associated virus) in genital 
secretions. Thus, vaginal contraceptives, which inactivate 
HIV should be an eifective barrier to transmission. 
The exposure to blood borne pathogens has always been 
of great concern to the community of individuals whose 
occupations require physical contact with tissue and body 
?uids and this concern has been heightened due to increase 
in the incidence of HIV. Current Occupational Safety and 
Health Administration (OSHA) standards regarding blood 
borne pathogens require the use of gloves in the processing 
and handling of any blood and/or body ?uids. 
There is a need in the pharmaceutical area for a paper 
products and plastic products coated with the antiviral 
composition of the invention. 
The composition of the invention meets the above objec 
tives and provides a high energy coprecipitate of nonox 
ynol-9 oligomers, polyvinylpyrrolidone and iodine (PVP-I). 
The composition shows a pronounced synergistic effect 
between the compounds which results in potent anti-HIV 
activity. 
DISCLOSURE OF THE INVENTION 
It is an object of the invention to provide a novel and 
potent composition possessing pronounced anti-HIV prop 
erties which is a high energy coprecipitate composition 
comprising N-9 oligomers and PVP and iodine. The PVP 
and iodine ingredients may be present in the coprecipitate 
composition as the complex PVP-I. 
The invention further provides a high energy coprecipitate 
composition which is in the form of a powder. In a preferred 
embodiment the invention provides a high energy copre 
5,492,692 
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cipitate composition including PVP-I which comprises 
about 0.09—9% w/w of iodine. 
In yet another embodiment, the invention provides a high 
energy coprecipitate composition of N-9 complexed with 
PVP comprising an antiviral concentration of free iodine of 
about 0.03% w/v or about 300 ppm. 
The invention additionally provides a high energy copre 
cipitate composition of N-9 complexed with PVP compris 
ing an antiviral concentration of free iodine providing about 
9.4 to 0.09% I2 providing an effective concentration of free 
iodine of 0.0094% w/v (94 ppm) and from about 11.8 —5.8% 
w/w of N9 providing an effective concentration of N9 of 
0.0058% w/v (58 ppm). 
In a further embodiment, the invention includes a high 
energy coprecipitate composition comprising an eifective 
?nal concentration of from about 58 pg/ml-ZOO pg/ml of 
N-9. 
The invention advantageously provides for a method of 
preparing a high-energy coprecipitate composition compris 
ing the steps of: 
(a) fractionating commercially available spermicide N~9 
to seventeen oligomers by a preparative high pressure liquid 
chromatography (HPLC) procedure; and 
(b) converting the oligomers or commercially available 
N-9 to a high energy coprecipitate with PVP and iodine. 
Preferred is a method of preparing a high-energy copre 
cipitate composition including the steps of: 
(a) fractionating commercially available spermicide non 
oxynol-9 (N~9) to seventeen oligomers by high pressure 
liquid chromatography (HPLC); 
(b) adding an N-9 oligomer obtained in step (a) with a 
10% or 1% solution w/v of PVP-I in a solvent, 
(0) placing the product of step (b) in an oil bath at about 
100° C., and allowing the solvent to evaporate. 
(d) obtaining a high energy coprecipitate of N-9, polyvi 
nylpyrrolidone (PVP) and iodine. 
Also included is a method of treating a female comprising 
administering to a female an effective amount of a high 
energy coprecipitate comprising N-9 oligomers, PVP and 
iodine to achieve a contraceptive and anti-HIV environment 
in the vaginal cavity. Thus, the invention provides spermi 
cidal and anti-IHV activity with no irritation to the cervical 
and vaginal epithelia, and may take the form of an elegant, 
free ?owing powder. 
The invention advantageously provides paper and plastic 
products coated with the antiviral composition of the inven 
tion. 
DESCRIPTION OF THE INVENTION 
The present invention describes methodology for the 
preparation and assessment of new chemical entities with 
pronounced anti-HIV properties. These chemical entities 
incorporate N-9 or selected N-9 oligomers, small amounts of 
iodine (I2) and the hydrophilic polymer PVP in such a way 
as to form high energy complexes, also known as copre 
cipitates. 
The novel composition of the invention comprises a high 
energy coprecipitate made from N-9 oligomers, PVP and 
iodine. A pronounced synergistic e?ect is obtained between 
the compounds, enhancing the anti-HIV activity of the 
compounds when in the form of a coprecipitate. Due to the 
synergistic effect of the compounds present in the high 
energy coprecipitate, the coprecipitate requires less of each 
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of the individual ingredients to achieve the desired anti-HIV 
result, than if the compounds were to be administered as a 
mixture. This is bene?cial as it reduces irritation to tissues 
caused by higher doses of N-9 and iodine and thus reduces 
the potential for HIV virus transmission. 
The high energy coprecipitates of the invention are for 
mulated by fractionating commercially available spermi~ 
cide, N-9, into seventeen oligomers by a preparative high 
pressure liquid chromatography (HPLC) procedure. 
Selected oligomers of N-9, or the commercially available 
N-9, are converted to high energy coprecipitates with PVP 
and various amounts of iodine (PVP-I). In a preferred 
embodiment the amount of iodine is about 0.09—9% w/w of 
iodine. The content of N-9 in the above complexes, in a 
preferred embodiment, ranges from 5.8-1 2% w/w. 
N-9 and its oligomeric components are inherently viscous 
liquids which are converted to free ?owing, water soluble 
powders by forming coprecipitates with PVP-l. Several 
combinations of iodine (I2), N-9 and PVP are utilized to 
produce powders which exhibit a variety of spermicidal and 
anti-HIV activities. 
In order to test and compare the anti-HIV activity of the 
high energy coprecipitates of the invention, the following 
assay procedure was performed. 
Procedure for Anti-HIV Activity Assessment 
High-titer suspensions (>106 infectious particles/ml) were 
incubated with each compound for 5 seconds, then imme 
diately diluted 1:50 onto cultures of human MT-2 cells for 
detection of infectivity. Cellular toxicities were observed 
and no antiviral activities were expected after the 1:50 
dilution, hence all antiviral activity would have resulted 
from the 5 second exposure. Infections were monitored by 
syncytium (giant cells) formation and Immune Fluorescence 
Assay (IFA). This assay utilizes an antiviral antibody with a 
?uorochrome attached to it through a covalent bond. Virus 
particles get to ?uoresce when viable, and therefore the 
degree of infectivity is quantitated. 
The results after 3, 5 and 8 days of incubation are shown 
in Table 1. In the control experiment, using the untreated 
virus, the MT-2 cells are 100% infected at the end of 3 days. 
A 1% value or less, indicates a complete inactivation of 
the virus as measured by the IFA method, i.e. no ?uorescent 
particles of the virus exist inside or outside the cells (Table 
1). 
Syncytia (giant cell) formation is assessed by staining 
techniques with subsequent microscopic examination. Syn 
cytia formation indicates invasion of the MT-2 cells by the 
virus. 
The method described is that of Monte?ori et al. “Evalu 
ation of Antiviral Drugs and neutralizing antibodies to 
human immunode?ciency virus by a rapid and sensitive 
microtiter infection assay”, J. Clin. Microbiol. 1988, Vol 26: 
231-235, incorporated herein by reference. 
Table 1 summarizes the results of anti-HIV activity 
assessment of two high energy coprecipitate powders of 
PVP-I and N-9. The ?rst was made with oligomers of N-9 
with an average molecular weight of 599 and the second 
with the oligomers of N-9 with an average molecular weight 
of 306. Both samples were coprecipitated with PVP, iodine 
and one of N9 oligomers mentioned above. 
5,492,692 
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TABLE 1 
Inactivation of Cell-Free and Cell-Associated l-lIV-ll 
3 days 5 days 8 
days 
IFA 
Syn 
DRUG cytia IFA2 IFA 
la CPE3 
PVP (11.8 mg/ml) 
1b -H+ >80% CPE CPE CPE 
PVP (0.236 mg/ml) 
2a — 
PVP (3.24 rug/ml) 
high MW N-9 
(0.2 mg/ml) 
PVP (0.0648 mg/ml) 
high MW N-9 
2(0.004 mg/ml) 
3a — 
PVP (5.8 mg/ml) 
low MW N-9 
(0.2 rug/ml) 
3b 
PVP (0.116 rug/ml) 
low MW N-9 
(0.004 mg/ml) 
4a — 
PVP-l (11.8 rug/ml) 
4b 
PVP-I (0.236 rng/rnl) 
5a — 
PVP-I (3.24 mg/ml) 
high MW N-9 
(0.2 mg/ml) 
PVP-I (0.0648 mg/ml) 
high MW N-9 
(0.004 mg/ml) 
10% 4-H- >80% 
>80% CPE CPE 
10% >80% 
>80% CPE 
>80% CPE CPE 
>80% CPE CPE 
— <1% — <1% 0% 
PVP-I (5.8 mg/ml) 
low MW N49 
(0.2 mg/ml) 
PVP-I (0.116 mg/ml) 
low MW N-9 
(0.004 mg/ml) 
>80% CPE 
1Details of experimental procedures are given in the test. 
2% IFA positive cells 
3CPE, viral-induced cytopathic effect was complete. 
l-IMW N-9 = 599 " 
LMW N-9 : 306 
IPA = Imuno-?ourescence assay 
The data in Table 1 show that PVP-I at a concentration of 
11.8 mg/ml completely inactivated cell-free and cell-asso 
ciated HIV-1. This represents approximately an effective 
concentration of 1.2% w/v of PVP~I or 0.12% w/v of free 
iodine (or 1,200 ppm of 12). 
A solution was made from a PVP-I and N-9 high energy 
coprecipitate. The coprecipitate composition was 94.2% 
w/w of PVP-I and 5.8% w/w of N-9, at a concentration of 
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3.24 mg/ml of PVP-I and 0.2 mg/ml of N-9 of an average 
molecular weight of 599. This composition achieved a 
complete eradication of the HIV virus in 30 seconds. 
The use of high molecular weight N~9 oligomers as a 
component of the anti-HIV coprecipitate composition 
decreases the systemic absorption of N-9 and therefore N-9 
is localized in the vagina and less toxic to the female. 
Similar anti-HIV results were obtained with a coprecipi 
tate of about 5.8 mg/ml PVP-I and about 0.2 mg/ml N-9 of 
an average molecular weight of 306. These results represent 
an antiviral concentration of free iodine of about 0.03% w/v 
(324 ppm). This level of iodine is not irritating to the vaginal 
epithelial tissue and desirably has no noticeable brown color. 
In contrast to the above results, when no iodine is present 
in a coprecipitate composition made with 94.2% w/w of 
PVP and 5.8% w/w of N-9, at a concentration of 3.24 mg/mL 
of PVP and 0.2 mg/mL of N-9 of an average molecular 
weight of 599, the antiviral properties of the product were 
substantially reduced (see Table l). 
A similar reduction of the antiviral properties was also 
observed when the product was made from a PVP/N-9 high 
energy coprecipitate of 94.2% w/w of PVP and 5.8% w/w of 
N-9, at a concentration of 3.24 mg/mL of PVP and 0.2 
mg/mL of N-9 of an average molecular weight of 599 (see 
Table 1). 
Thus, in a preferred embodiment, the presence of 324 
ppm iodine in the case of high molecular weight (599) N-9 
and 580 ppm of iodine, in the case of the lower molecular 
weight N9 (306) importantly adds to the synergistic anti 
HIV e?ect of the high energy coprecipitate. The iodine and 
N-9 both act in a synergistic manner when complexed with 
PVP. 
Other solutions made from PVP~I and N9 coprecipitate 
in accordance with the invention include 94.2% of PVP-I 
and 5.8% of N9 with an average molecular weight of 599. 
A further solution made from PVP-I and N-9 coprecipitate 
comprises 94.2% of PVP and 5.8% of N9 with a weight 
average molecular weight of 306. 
The chemical union of the iodine, PVP and several 
oligomers of the sperrnicidal agent N-9 with different 
molecular weights results in an impressive synergistic action 
of iodine and the spermicide N-9 against human immuno~ 
de?ciency virus (HIV) (Tables 1 and 2). 
The coprecipitate of the invention shows that the syner 
gism between iodine and N-9 is of such magnitude that 
solutions with even smaller concentrations of these species 
can be used. Again, this is bene?cial as it reduces vaginal 
irritation and thus reduces the potential for HIV virus 
transmission. Indeed, a complete eradication of the I-HV 
virus was obtained when coprecipitates of PVP, iodine and 
N-9 solution, containing as low as 58 ppm of N-9 and 940 
ppm of PVP-I (94 ppm of iodine), were utilized (see Table 
2). 
TABLE 2 
Concentration on Virus 
[ug/mL = ppm] Syncytia lFA Position 
Compound N9 PVP-I % Cells % 
No drug —— — 100 100 
KY048 58 940 0 0 
KYOSO 117.4 10 10 5 
5,492,692 
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TABLE 2-continued 
KY052 118 0 30 10 
Composition of KY Coprecipitates 
PVP PVP-I I2 N-9 
% ppm % ppm % ppm % ppm 
KY048 0 0 94.20 940,000 9.40 94,000 5.80 58,000 
KYOSO 88.58 885,800 0.90 9,400 0.09 940 10.52 105,200 
KY052 88.20 882,000 0 0 0 0 11.8 118,000 
The synergistic etfect against the HIV is so signi?cant that 15 EXAMPLE 1 
the above PVP-l/N-9 solution at concentrations as small as _ _ _ _ _ 
58 ppm of N_9 and 94 ppm of iodine are eifective, against The various compositions of coprecipitates are made 
the HIV Virus (Table 2)_ according to the following general procedure: Stock solu 
In addition to the unexpected synergism between the tions of approximately 1% w/v OfPVPJ and 1% w/v N'g are 
compounds, the coprecipitation of iodine, N-9 and PVP 20 made m ethanol or méthaflol' _ _ 
results in the formation of freely ?owing powders which The N-9 Stock S01l1t10n lsadded dropwise toan ahquot of 
enable the prepdmtion of elegant Solid pharmaceutical foi_ the PVP-I stock solution with stirring. It is critical that the 
mulations with control release properties. The coprecipitate FWD soluFlons are mlxed a? a Yer)’ Slow rate- Thus’ the 
powders are particularly useful in the design of acceptahie introduction of the N-.9 solution, into the round bottom ?ask, 
solid formulations intended for vaginal, or other appropriate 25 colltalmng the PVP'I’ must be done dropwlse but over a 
um period of not longer than 1.5 hours. 
The coprecipitate composition may be administered in the subseqflemly’ the §°1vfmt is evaporate‘; from the PVOP‘U 
form of solid formulations, such as tablets or capsules, or as N‘9 Sohmon by heatmg 1“ a preheated 011 bath a: 100 C 
ointments, creams or suppositories. In a preferred ernbodi- The temperature must be kept Constant at 100 C- The 
ment the composition is administered in the form of a 30 evaporation process should last between 1-2 hours but no 
capsuis or tablet longer than two hours. 
Tablets, capsules, ointments, creams or suppositories may E AMPLE 2 
be formulated according methods known in the art such as X 
those disclosed in Remington ‘s Pharmaceutical Science, If a “glassy” coprecipitate is obtained following the 
18th Ed. pp. 1602-1712, incorporated herein by reference. 35 general procedure described in example 1, diethyl ether is 
In contrast, N-9 by itself is a viscous liquid which cannot mixed with lb‘? residue- Upon eYaporation of the diethyl 
be formulated as a powder in solid dosage forms such as ether a crystaume powder 15 obtained 
tablets or capsules. N~9 has heretofore been unable to form 
elegant tablets or capsules which are preferred by the user EXAMPLE 3 
over creams and suppositories. Additionally, at its generally 40 If a ?nely divided crystallin? powder of the PVP_UN_9 
?acgfteil 6513:3023; gligrgrsuggglmfmtlgiggzzmiial(gp?ggi; coPreciPitate is desired, following the Procedure described 
d 1,y_ ffh ’ , at l g g p in Example 1, the residue, received after evaporation 
an Hung Q ‘T’ vagm van t‘ _ i ' described in Example 1, is dissolved in a mixture of metha 
At concentrattlops below PPm nelther 1991115 nor N'9 45 nol/1,4 dioxane (1:4 ratio v/v) and subjected to freeze 
am known to lmtate sensltlve membrane llmngs of the drying for at least 12 hours. A ?ne crystalline powder is 
human body. Thus, the coprecipitate powders can be for- obtained by the frceze_drying step 
mulated into drug delivery systems that can release their 
active ingredients in a predictable manner without causing EXAMPLE 4 
irritation to surrounding membrane linings. 5O _ _ t _ 
The powders of the invention are acceptable to the user commerclally available nonoxynol'g cont'fnmng Sever? 
and furnish prolonged protection against AIDS and sexually teen oligomers with an average molecular weight of 599 is 
transmitted diseases (STDS) with minimal absorption to the utilized as a component in the general procedure described 
Systemic circulation in Example 1. The oligomer of N9 is isolated by the HPLC 
' ddild'Wal BA. .1 T'. 
The main ingredient in the powders of the high energy 55 31:6; 62331032565061 25852568. waltitralg ‘(A9321 ‘($3013 
coprecipitates, described in this invention, is the hydrophilic Phfmn Res 8, 40'9_4'11_ and Walter B’ 'et at" (1991) 
giggle; fP 23521312221?’ ngilqvlvitnacrltls 631226122: gfogfigrilg Pharm. Res. 8: 403-408, incorporated herein by reference). 
only enhances the solubility of the various N-9 oligomers b Briifgy’ ‘die sepagtaon 1S ?hlevegltiy a prfa’garanve Zor' 
but also contributes to the synergistic action of N-9 and 60 ax' 2 60 um ( mm’ pmX ' mm 1' ')' 
iodine against the AIDS virus. Thus, in a most important 
aspect of the invention, the active ingredients (N-9 and EXAMPLE 5 
iodine) are present in the powder in such minuscule quan- Stock solutions of N_9 (250 Irig/m1) were prepared in 
tities that are known not to irritate membrane linings of the tetrahydrofuran A 1_() m1 aliquot was Separated on a pm 
body‘ 65 parative Zorbax-NH2 7 pm column, 250 mm><2l.2 mm ID, 
The following examples are given to illustrate the inven 
tion, but are not to be construed as limiting. 
using a linear solvent gradient from 98% A-2% B to 50% 
A—50% B in 90 min., where A=tetrahydrofuran:hexane 
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(20:80, v/v) and B=water:2-propanol (10:90, v/v) delivered 
at 9.9 ml/rnin at ambient temperature and detection at 280 
nm. The HPLC system used was a Waters HPLC system 
(Millipore, Waters Chromatography Division, Millford, 
Mass.) consisting of two Waters Moldel 510 I-IPLC pumps, 
a Waters Model 680 gradient controller, a Waters Model 440 
Absorbance detector (280 nm), and a Waters Model SE120 
dual channel recorder. Samples were introduced via a Rheo 
dyne Model 7125 loop injector equipped with a 100 pl loop 
onto the HPLC column. Seventeen oligomers were col 
lected, concentrated and reinjected onto the analytical sys 
tem for further puri?cation. The 599 molecular weight 
fraction and 305 molecular weight fraction were separated 
from the other fractions. 
A 10% or 1% solution of w/v of PVP-I and the MW 599 
fraction of the compound of nonoxynol-9 (N9) (isolated as 
set forth above) in absolute ethanol (methanol) was made. 
Both solutions were added via dropping funnels into a round 
bottom ?ask. It is important in this step to allow the dropping 
of the two solutions to continue for 1.5 hours. Thus the 
addition of the two solutions must take place slowly. 
To an oil bath which had been preheated to 100° C., the 
?ask was placed and the solvent allowed to evaporate. It was 
important to make sure that the temperature was well 
controlled during the evaporation process. The evaporation 
process should take between 1 and 2 hours. The evaporation 
should not take place longer than 2 hours. 
A high energy coprecipitate of the compounds is obtained. 
Examples 6—8 show formulations of the high energy 
coprecipitate of the invention. 
EXAMPLE 6 
A high energy coprecipitate composition of 940.09% I 
w/w and 11.8—5.8% N-9 w/w. The high energy coprecipitate 
provides anti-HIV protection at an eifective concentration of 
about 3.24 mg/ml of PVP-I and 0.2 mg/ml of N-9 of an 
average molecular weight of 599 in a tablet formulation. 
EXAMPLE 7 
A high energy coprecipitate providing anti-PHV protec 
tion at an effective concentration of about 5.8 mg/ml PVP-I 
and 0.2 mg/ml N-9 of an average molecular weight of 305 
in a capsule formulation. 
EXAMPLE 8 
A high energy coprecipitate providing anti-HIV protec— 
tion at an effective concentration of about 58 ppm of N-9 and 
940 ppm of PVP-I or 94 ppm of iodine in a cream formu 
lation. 
EXAMPLE 9 
A multiple dose penile irritation study of the high energy 
coprecipitate composition of the invention identi?ed below 
was conducted in the rabbit. The purpose of this study was 
to evaluate the potential for mucosal irritation of a solution 
administered to penile tissue. Animal treatment was begun 
and completed in seven days. 
Materials: The high energy coprecipitate composition was 
identi?ed and handled as follows: 
Test Article: 
Spermicidal/anti-HIV agent 
Storage Conditions: 
Controlled room temperature 
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Vehicle: 
0.9% sodium chloride USP solution (SC) 
Preparation: 
Following instructions provided, a 0.323 mg portion of 
the test article was solubilized in 100 ml of SC. The 
solution was kept refrigerated until use. Each dosing 
day, a suf?cient amount of the test article solution was 
removed and brought to room temperature. The vehicle 
(SC) was dosed “neat” to serve as the control. 
Condition of Extracts: 
SC Test: clear brown 
SC Control: clear 
Methods 
Animal Manaqement: 
Five healthy male rabbits of the New Zealand White 
variety were obtained from USDA licensed suppliers. These 
animals were acclimated to the laboratory. 
Rabbits, identi?ed by ear tag or tattoo and weighing 2.5 
kg to 2.6 kg, were individually housed in suspended cages 
and received a commercially pelleted rabbit feed on a daily 
basis; tap water was freely available. No diet or water 
analysis was performed since there were no contaminants 
suspected that could interfere with this study. Animal hus 
bandry and environmental conditions conformed to current 
standard operating procedures which are based on the 
“Guide for the Care and Use of Laboratory Animals,” NIH 
Publication No. 85—23. 
Experimental Procedure 
Three rabbits each received a single 2.0 ml treatment of 
the high energy coprecipitate solution on each of 5 consecu 
tive days. Two additional rabbits received a similar dose of 
the control vehicle. The appropriate test article solution or 
control vehicle was applied to the penis and surrounding 
prepuce. (Note: Not all of the test article solution or control 
vehicle remained in contact with the penile tissue.) Animals 
were maintained in restrainers for 4 hours and then returned 
to their respective cages. 
Each animal was observed daily for general health. Rab’ 
hits were weighed just prior to ?rst treatment and at study 
termination. The penile tissue was observed for signs of 
irritation the day following each application (prior to the 
next application) and also the day following last treatment in 
accordance with the following scoring scheme. 
0=no change 
1=slight redness/or swelling 
2=moderate redness, slight swelling 
3=moderate redness and swelling 
4=marked redness and swelling 
Mucosal irritation was based on a comparison between 
test and control scores. Average irritation scores of 2 or 
greater were considered as slight irritation; scores of 3 or 
greater were considered as signi?cant irritation. 
Results 
Clinical Observations: All animals appeared clinically nor 
mal throughout the study 
Body Weight and Macroscopic Examinations: 
Body Weight and Macroscopic Examination: 
Rabbit Weight (kg) 
Number Day 0 Day 5 Macroscopic Observations of Vagina 
75384 T 2.4 2.4 Macroscopically normal 
75303 T 2.6 2.6 Macroscopically normal 
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-continued 
Body Weight and Macroscopic Examination: 
16 
Rabbits, identi?ed by ear tag or tattoo and weighing 2.4 
kg to 2.7 kg, were individually housed in suspended cages 
and received a commercially pelleted rabbit feed on a daily 
Rabbit Weight (kg) basis; tap water was freely available. No diet or water 
5 . . . 
Number Day 0 Day 5 Macroscopic Obsemm-ons of vagina analysis was performed s1nce there were no contammants 
suspected that could interfere with this study. Animal hus 
75296 T 2.5 2.6 Macroscopically normal - - - 
75322 C 25 2'6 Mamsmpicany mm bandry and environmental conditions conformed to current 
75302 C 2;; 2'8 sligm redness standard operating procedures which are based on the 
10 “Guide for the Care and Use of Laboratory Animals,” NIH 
(Tzjéffml Publication No. 85-23. 
_ Experimental Procedure: 
Evaluanon _ _ _ f _ Three rabbits each received a single 2 ml instillation of the 
The avarage mucosal lmtanon Scope 0? the test ammals high energy coprecipitate solution into the vagina for 5 
was 0 as compared to O for the control anlmals. There was 15 . . . . . . . 
. . . . . . . consecutive days. Two additional rabbits received a similar 
no evidence of sigm?cant irritation in the test or control _ _ , 
tissues of the rabbits_ dose of the control solution. The appropriate test article or 
Conclusion: Under the conditions of this study, the high control Soluuon was Introduced. Into the_ vagmal vault 
energy coprecipitate composition was not considered an through a 50ft hlbbcr catheter mclstchcd Whh thc Prcpam 
initam to the penile mucosal tissues of the rabbit 20 tion. Animals were returned to their cages after treatment. 
Each animal was observed daily for general health and for 
EXAMPLE 11 external signs of irritation around the opening of the vaginal 
' _ _ _ _ _ _ vestibule. Rabbits were weighed just prior to ?rst treatment 
A vaginal irrétagonstudyiof the1 h1g2 ecrlieggy coprecipitate and at study termination 
composltlon 0 t 6. mvcnnon 1 en“ 6 e ow was con' 25 On the day following the last treatment the rabbits were 
ducted 1n the rabbit. The purpose of the study was to . . . . . . 
. . . . . euthanatized by an intravenous IIIJCCHOII of a sodlum pen 
evaluate the potential for mucosal tissue irritation of a b b. all b d h _ d E h _ d 
material administered intravaginally to rabbits for 5 con- F0 at It ase em afmsla rug‘ ac V851“ was rem°ve_ 
secutive days. Animal treatment began and was completed 1“ tow’ opened longltudmany and exammed macroscopl' 
within a 5 day pen-0d 3O cally for signs of in?ammation. Representative sections of 
Materials: The high energy coprecipitate composition of the each vagina were preserved in 10% neutral buffered forma 
invention was identi?ed and handled as follows: lin and histologically processed (hematoxylin and eosin 
Test ??iClBI stain) for microscopic evaluation by a board certi?ed 
Spermicidal/anti~HIV agent pathologist. The assessment for mucosal irritation potential 
Storage Conditions: - 35 was based on the histopathological ?ndings. 
Controlled room temperature Results and Clinical Observations: All animals appeared 
Control Article: clinically normal throughout the study. 
Weight (kg) OBSERVATIONS 
Rabbit Number/Group DAY 0 DAY 5 DAY 1 DAY 2 DAY 3 DAY 4 DAY 5 
75333 Test 2.6 2.5 O 0 0 O 0 
75342 Test 2.6 2.6 0 0 0 0 0 
75337 Test 25 2.6 0 O O O 0 
75339 Control 2.5 2.5 O 0 0 0 0 
75360 Control 2.6 2.6 0 0 0 0 0 
0.9% sodium chloride USP solution (SC) 50 Microscopic Evaluation: The average mucosal irritation 
Preparation: score for the test animals was 5 as compared to 6 for the 
A 0.323 mg portion of the test article was s olubilized in control animals- Individual results of the Pathology ?nd 
lOO ml of SC. The solution was kept refrigerated until h1g3 appear in the attached microscopic evaluation 
use_ Each dosing day, a Su?icicnt amount of the test 55 Conclusion: Under the conditions of this study, the average 
article solution was removed and brought to room mucosal irritation score of the vaginal tissues treated with 
temperature’ The vehicle (SC) was dosed “neat” to the test article solution was within acceptable limits. The 
Serve as the contrOL test article was not considered an irritant to the vaginal 
Condition of Solution mucosal tissue of the rabbit. 
SC I t 1 ti _ 1 b 60 II. PVP-I/N-9 coated paper products 
65 so u on‘ 0 car rown The data set forth above shows that the chemical union of 
SC control: clear iodine, polyvinylpyrrolidone (PVP) and several oligomers 
Methods: Ahlmal Management of the spermicidal agent nonoxynol-9 (N-9) with different 
Five healthy female rabbits of the New Zealand White 65 molecular weights results in animpressive synergistic action 
variety were obtained from USDA licensed suppliers. These 
animals were acclimated to the laboratory. 
of iodine and the spermicide N-9 against human immuno 
de?ciency virus (HIV) (Tables 1 and 2). 
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The coprecipitation of iodine, N-9 and PVP results in a 
synergism of such magnitude that very small concentrations 
of these chemical species posses good anti-HIV properties 
(Table 2). Indeed, complete eradication of the HIV-virus was 
obtained when such coprecipitates were used containing 
concentrations of PVP-I and N-9 of 940 ppm (94 ppm of 
iodine) and 58 ppm, respectively. 
In addition to the unexpected synergism between the 
above chemical species, the coprecipitation of iodine, N-9 
and PVP results in the formation of freely ?owing powders 
which enable the preparation of elegant solid pharmaceutical 
formulations which otherwise would be very di?icult to 
produce. 
One application of the antiviral composition of the inven 
tion is the production of paper coated products or sheets of 
paper which possesses the ability to destroy the HIV virus 
instantly upon contact with biological ?uids containing this 
virus. Such products, for example include, but are not 
limited to coated surgical gowns, paper masks, paper made 
bed covers and other paper liners utilized in hospital beds 
and on physician’s examination tables. Any paper product 
can be coated with the high energy coprecipitate powder of 
the invention. 
Exposure to blood borne pathogens has always been a 
primary concern for the community of individuals whose 
occupations require physical contact with tissue and body 
?uids. This concern has heightened due to the alarming 
increase in the incidence of Human Immunode?ciency Virus 
(HIV) infections. See Bartlett, J. G. “HIV Infection and 
Surgeons”, Current Problems in Surgery, Wells, S. A., ed. 
Moseby~Year Book, Inc. 1992. 
The community of concerned individuals is broad based 
and includes physicians, nurses, technical staff as well as 
ancillary personnel such as housekeeping staff. The Centers 
for Disease Control (CDC) has reported on 137 cases in 
which HIV was probably acquired through occupational 
exposure. 37 of these cases, which includes 4 surgeons have 
been strongly con?rmed. The majority of these infections 
are thought to have occurred as the result of hypodermic or 
surgical needle punctures. See, CDC. “Recommendations 
for Assisting in the Prevention of Perinatal Transmission of 
Human T-Lymphotrophic Virus Type lII/Lymphadenopathy 
Associated Virus and Acquired Immunode?ciency Syn 
drome”, MMRW 1985, 31:577—580. 
In addition, the CDC has documented at least 3 healthcare 
workers who have acquired I~HV through cutaneous or 
rnucocutaneous contact. See, CDC, “Update: Human Immu 
node?ciency Virus Infection in Health-Care Workers 
Exposed to Blood Infected Patients”, MMRW 1987, 
36:19:285-289. Such transmission is thought to occur via 
breakdown in the integrity of cutaneous, rnucocutaneous 
barriers with eventual exposure and infection of the host’s 
immune cells. This type of transmission can occur from a 
myriad of sites including open cutaneous wounds, dermatitis 
with exudant, cuticular infections, etc. 
The process of making the coated paper products of the 
invention is set forth below. The present invention broadly 
encompasses any paper product comprising an anti-PHV and 
antibacterial composition. In a preferred embodiment the 
paper product comprises anti-HIV and antibacterial compo 
sition which is applied to the paper product as a microen 
capsulated coating. 
In a most preferred embodiment the anti~HIV and anti 
bacterial composition is the high energy coprecipitate of 
PVPI/N-9. Mixtures of the drug (PVPI/N~9) were made and 
these were utilized as coating solutions (Tables 3 and 4). A 
thin layer of the drug was formed by spray-coating of the 
various solutions onto the paper. 
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Alternatively the paper may be coated by any coating 
process, including straight or roll coating procedures. The 
following coating methods may also be used. 
COATING TECHNIQUES 
1. Brush Coating 
2. Roll Coating 
Pressure 
Kiss 
Reverse Roll 
3. Rod Coating 
4. Knife Coating 
5. Print Coating 
Flexo 
Gravure 
6. Spray Coating 
Cold Spray 
Hot Spray 
Electrostatic Spray 
7. Dip Coating 
For example, the high energy coprecipitate of the inven 
tion may be spray coated onto the paper material with a 
Binks spray gun model Mach 1 HVLP. When coating or 
spray coating, the high energy coprecipitate of the invention 
or other drug the “coat weight” (weight per unit area of 
“dry” non-volatile material which is applied to the paper 
substrate) is in the range of 2-30 g/m2 based upon 50—75% 
drug concentration in the coating. In a preferred embodiment 
the coat weight is in the range of 2-8 g/m2 based upon 
50-75% drug concentration in the coating. 
Other drugs which may be effective as anti-HIV and/or 
anti-bacterial materials may also be coated onto the paper 
material. These compounds include: 
Acylclovir (Burroughs & Wellcome Corp.)——dose range: 
200-1000 mglcmz. 
Ribavirin (ICN Pharrnaceuticals)——dose: 
mglcmz. 
Retrovir (AZT) (Burroughs & Wellcome Corp.)—dose: 
200-1500 mglcmz. 
Interferon alfa-n3 (Purdue Frederick, Inc.)—dose: about 
0.5 million I.U. (I.U.=International Units) 
Chlorhexidine=antirnicrobial agent (2-4%) 
PVP-Bromine 
In a preferred embodiment the coating material is the high 
energy coprecipitate PVP-I-N9 combination. Mixtures of 
the antiviral/antibacterial agents are also preferred. 
When PVP-I-N9 coprecipitate is applied to the paper 
material a lower concentration of the drug is needed to be 
effective. A coat weight of 5.40 mg/cm2 is more preferred 
when a PVP-I-N9 coprecipitate is applied to paper. A lower 
concentration of PVP-I-N9 coprecipitate translates to lower 
coat weights at 75% drug concentration or lower drug 
concentration or both. 
Alternatively, any drug or the high energy coprecipitate 
can be attached to the surface of the paper by a microen 
capsulation process. Microencapsulation is the enclosure of 
an inner material, such as a drug, within an outer material 
processed into the form of rnicrospheres in the micron size 
range of 0.1-1.50u. The outer material which forms the 
rnicrosphere is designed to be a protective coating and can 
be formulated with semipermeable membrane or slowly 
dissolving properties to achieve controlled release of the 
inner material. 
about 20 
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One microencapsulation technique that can be used is 
dissolving the inner material in hydrophobic liquid and then 
fornring an emulsion with a water soluble polymer with high 
speed mixing. Droplets of inner material in a hydrophobic 
liquid surrounded by rnicrospheres of water soluble polymer 
are then formed. 
Another microencapsulation technique. is heating a low 
melting inner material to a molten state. This molten state 
material is then added to an aqueous solution of water 
soluble polymer forming an emulsion with high speed 
mixing. Droplets of molten inner material encased in micro 
spheres of water Soluble polymer are then formed. Microen 
capsulation solutions can be coated on a variety of substrates 
with conventional coating techniques. In a preferred 
embodiment a drug or the high energy coprecipitate com 
position is microencapsulation coated onto the paper mate 
rial. 
Tables 3 and 4 describe preferred embodiments of the 
components utilized for ?lm coating solutions and examples 
of their compositions, respectively. 
In a preferred embodiment the coated-paper was prepared 
as follows: Paper taking the form a commercial surgical 
paper gown was sprayed by a solution of the PVP-I/N-9 
(drug) in ethanol-water (8:1). 
The composition of coating solution is represented by 
example D of Table 4 and was as follows: Drug (PVP-I/N-9) 
75% w/w; HPMC 6% w/w; PEG 1450 14% w/w; talc 15% 
w/w and Tween 80-6% w/w. 
The ?nal concentration of the total amount of drug on the 
paper was found by titration of iodine (using the United 
States Pharrnacopeia) to be 4.05 mg/cm2. Of this amount 
0.375 mg is iodine, 0.25 mg is N-9 and the remaining (3.43 
mg) is PVP. As little as 0.5 mg/cm2 of the drug (PVP-I/N-9) 
is needed to kill completely the virus (1X105 infectious, 
cell-free virus particles per 0.1 ml of contaminated blood). 
If one considers that approximately one to two drops of 
blood (0.05—0.1 ml) are to be absorbed per square centimeter 
(cm2) of the coated paper. Table 1 shows approximately 300 
pg of the drug are needed to kill the virus in 0.1 ml of blood. 
Thus, if 1 cm2 of paper absorbs two drops of blood (0.1 ml), 
the e?ective amount of antiviral compound required per cm2 
of paper is about 0.3 mgIcmZ-about 0.6 mglcmz. 
Film coating solutions may contain polymers, colorants, 
glidants, plasticizers, and vehicles known to those of skill in 
the art. 
The following tables provide examples of the components 
of the coating solutions for paper coated products of the 
inventions. 
TABLE 3 
COMPONENTS FOR FILM COATING SOLUTIONS 
POLYMERS: 
. I-Iydroxypropyl Methyl Cellulose (HPMC) 
2. I-Iydroxypropyl Methyl Cellulose 
Phthalate (HPMCP) 
. Hydroxypropyl Cellulose (HPC) 
. l-Iydroxypropyl Methyl cellulose 
Acetate Succinate (HPMCAS) 
. Eudragit RS PO* 
. Eudragit R.L PO* 
. Eudragit E 100* 
. Polyethylene glycol (PEG 1450, PEG 
8000, PEG 6000) 
9. Ethyl Cellulose (EC) 
COLORANTS: 
1. Titanium dioxide 
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TABLE 3-continued 
COMPONENTS FOR FILM COATING SOLUTIONS 
2. Aluminum lake 
3. Red iron oxide 
4. Dyes 
PLASTICIZERS: 
. Glycerin 
. Propylene glycol 
. Polyethylene glycol 
. Triacetin 
. Triethyl citrate 
. Diethyl phthalate 
. Dibutyl phthalane 
GLIDANT S: 
. Talc 
. Magnesium stearate 
VEHICLES: 
. Alcohols 
. Ketones 
. Esters 
. Chlorinated hydrocarbons 
. Water 
*Note: 
PO means powder supply 
100 means granulate supply 
Eudragit RL - copolymer of acrylic and methacrylic acid esters with low 
content of quaternary ammonium groups. 
Eudragit E - copolymer of dimethyl aminoethyl methacrylate and neutral 
methacrylic acid ester. 
Table 4 below includes some examples of preferred 
embodiments of the coating solutions of the invention. 
TABLE 4 
EXAMPLES OF COATING SOLUTIONS 
A 
antiviral composition 50-75 % 
HPMCAS 10-20% 
Triethyl citrate 18-50% 
Talc 3.0—7.0% 
Water/Ethanol (20:80)% 
B 
antiviral composition 50—75% 
HPMCP 6-20% 
Methylene chloride/Ethanol (1:1) 
C 
antiviral composition 50-75% 
HPMC 6-20% 
PEG 6000 12-25% 
EC or I-IPMCP 5-15 % 
Methylene chloride/ethanol (1:1) 
2 
antiviral composition 50-75% 
HPMC 6—l0% 
REG 1450 9-25% 
Talc 7-10% 
Tween 80 5—7% 
Water/ethanol (8: 1) 
E_ 
antiviral composition 50-75% 
Eudragit RL PO 10-15% 
or Eudragit RS PO 
PEG 6000 12-25% 
Talc 7-10% 
Tween 80 5-7% 
Water/ethanol (7:3) 
F 
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TABLE 4-continued 
EXAMPLES OF COATING SOLUTIONS 
antiviral composition 50-75% 
Eudragit E 100 5-10% 
PEG 6000 12-25% 
Talc 7—l0% 
Tween 80 5—7% 
Water/ethanol (2:8) 
Coating solutions may be applied to the surface of the any 
paper product or between plys of the paper products. 
ANTI-HIV STUDY 
A study was conducted to test the anti-HIV properties of 
paper materials coated with the anti-HIV compound of the 
invention. 
Tests were performed by placing 0.5 ml of virus (HIV 
llllB), >106 infectious particles/ml) in the center of an area 
of a surgical gown which had been treated with the anti-HIV 
PVP-I/N-9 high energy coprecipitate compound of the 
invention. The drop of virus was swirled until it covered an 
area of approximately 2 inches in diameter. After a 2 minute 
incubation, 50 ul of the virus suspension was removed from 
the treated area of the surgical gown and diluted in 1:100 in 
growth medium. Fifty microliters of diluted virus was then 
added to 200 111 of MT-2 cells in a 96-well plate. Infections 
were monitored by syncytium (giant cell) formation, immu 
no?uorescence assay (IPA) and p24 assay for a period of 11 
days. As a separate control, the original virus suspension 
was tested before adding it to any materials (i.e. untreated 
virus). In addition, an untreated gown was tested which was 
not treated with PVP-I/N-9 high energy coprecipitate. 
Results: Untreated virus and virus placed on control gown 
fabric produced syncytia and complete cell killing after 5 
days of incubation with MT-2 cells. Virus that had been 
placed on both of the treated gown fabrics produced no 
syncytia after 11 days, and all the cells were negative by [FA 
and p24 assay for viral antigen synthesis, indicating that all 
infectious viral particles had been inactivated. Thus, the 
treated paper products inactivate HIV virus and provide a 
barrier to HIV virus. 
ll]. PVP-I/N-9 coated plastic products 
In accordance with the present invention, it is also desir 
able to coat plastic, polymer or latex products with the 
antiviral/antibacterial compound of the present invention. 
Any plastic product may be covered with the antiviral 
powder of the invention, including, for example, plastic 
gloves, including surgical gloves and latex condoms, includ 
ing male and female condoms. 
Current Occupational Safety and Health Administration 
(OSHA) standards regarding blood borne pathogens 
requires the use of gloves in the processing and handling of 
any blood and/or body ?uids. These standards are continu 
ally being reviewed and the development of additional 
safety and protection devices are being investigated. These 
include devices or barriers that contain antiviral compounds. 
A study was performed to evaluate the dermatologic 
tolerance of the antiviral powder of the invention when used 
as an antiviral barrier worn topically inside surgical and 
medical gloves. The study examined the dermatologic aller 
genic properties of the powdered compound when worn by 
individuals for extended periods of time. The results of the 
study are equally applicable to safety of condoms coated 
with the antiviral composition of the invention. 
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A blinded study was designed to address the irritability of 
antiviral powder of the invention when utilized as a topical 
agent on the epidermis of the hand. Dermatologic contact 
was achieved via the use of commercially available, non 
treated latex surgeon’s gloves to which 250 milligrams of 
antiviral powder was applied to the inner surface of either 
the right or left glove. The remaining gloves remained 
untreated. 
The study population consisted of 25 healthy volunteers. 
Males or females between the ages of 18-75 years who will 
be recruited for this study. Only individuals with no existing 
rashes, eczema, abrasions, cuts or dermatologic abnormali 
ties were included in the study. 
Control gloves and treated gloves were provided to the 
volunteers. Distribution and collection of the gloves prior to 
and after exposure was coordinated by the principal inves» 
tigator. Each treatment glove (latex or nylon) had approxi 
mately 250 mg of antiviral powder added to the inside 
lining. 
In keeping with current standards and providing addi 
tional barriers for protection of healthcare workers, a sample 
of PVP-I/N-9 containing 940 ppm of I2 and 62,000 ppm of 
N9 was prepared which was placed in latex surgical gloves 
for use as additional protection to be used in medical 
treatment, and in surgical and handling procedures. 
Antiviral compound was in powder form and of the same 
consistency of commercially available glove talc or corn 
starch. Control gloves were of the same material (latex or 
nylon) and were not treated with any additives. 
At the conclusion of the study all materials including 
exposed gloves were returned. Clinical assessment of each 
volunteer was made by a board certi?ed dermatologist. 
Each volunteer was examined by the physician immedi 
ately prior to exposure and was assessed for any pre-existing 
dermatologic condition. Once the physician has assessed the 
volunteers’ dermatologic condition and determined that no 
preaexisting condition existed, the volunteer were allowed to 
initiate the study. Photographs (135 mm, 100ASA) were 
made of each hand on both the dorsal and ventral surface of 
each volunteer. Volunteer codes and dates were included in 
the photographs. 
Volunteers’ dermatologic condition were assessed by the 
physician at seven day intervals during the exposure period 
and at the end of a seven day period following the exposure 
period. Each volunteers’ hands were photographed imme 
diately following the 21 day exposure period in the same 
fashion as described above. All clinical assessments were 
accompanied by written evaluations of the physician. 
Any abnormal dermatologic condition such as itching, 
eczema, swelling, numbness or any other abnormality expe 
rienced by the volunteer was required to be reported to the 
principal investigator immediately and any such volunteer 
was withdrawn from the study. Clinical assessment and 
evaluation by the physician was made within 24 hours. 
Photographs were made of the volunteers hands, as 
described earlier, for documentation. 
An assessment was performed of the dermatologic safety 
and allergenic properties of the antiviral powder with spe 
ci?c kill properties for the human immunode?ciency virus. 
Each volunteer was examined by the physician immedi 
ately prior to exposure for detection of any preexisting 
dermatologic condition. Twenty-?ve human volunteers, 16 
male, 9 female with average age of 36 years, were exposed 
to 250 mg of the compound contained in powder free 
examination gloves. Powder free examination gloves with 
out the antiviral agent was worn on the opposite hand and 
served as a control. 
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Gloves were worn by the individuals for 4 hours/day for 
21 consecutive days. Dermatologic examinations were per 
formed at 7 day intervals. Results: All 25 subjects completed 
the 21 day exposure period with a total exposure time of 
2,224 hours (Table 5). Average exposure time per day was 
4.21 hours with the greatest exposure being 5.24 hours/day 
(Table 5). Dermatologic evaluations revealed no allergenic 
or abnormal derrnatologic conditions arising from the expo 
sure to the antiviral compound. Two subjects were reported 
to have known derrnatologic reactions with commercially 
available gloves treated with talc or cornstarch. Examina 
tions from these subjects were negative. 
It was concluded that the use of an antiviral compound 
designed for the use in surgical, examination or handling 
gloves as an antiviral barrier was shown not to cause any 
derrnatologic reactions or abnormalities to the hands. The 
PVP-I/N-9 drug will provide an additional eifective and safe 
barrier for individuals whose occupations require the physi 
cal contact with human tissue and/or body ?uids. This group 
of individuals is not limited to but includes physicians and 
surgeons, nurses and ancillary personnel such as housekeep 
ing personnel. 
TABLE 5 
HAND IRRITABILITY ASSESSMENT OF THE ANTI 
VIRAL POWDER (PV-IlN-9) IN HUMAN VOLUNTEERS 
TOT. N0. of MALE SUB]. 16 
TOT N0. of FEMALE SUB]. 9 
AVG. AGE of SUB]. 36 
SD. of AGE 13 
OLDEST SUB]. 62 
YOUNGEST SUB]. 18 
AVG. AGE of MALE SUB]. 35 
SD. of MALE SUB]. AGE 14 
OLDEST MALE SUB]. 61 
YOUNGEST MALE SUB]. 18 
AVG. AGE of FEMALE SUB]. 38 
SD. of FEMALE SUB]. AGE 12 
OLDEST FEMALE SUBJECT 62 
YOUNGEST FEMALE SUB]. 19 
TOT. NO. OF EXP. HRS 2224 
TOT. NO. OF EXP. DAYS 528 
AVG. EXP. per SUB]. (I-Ir.) 88.96 
AVG. EXPJSUBJJDAY (Hr) 4.21 
LONGEST EXP. (HR) 110 
SHOKI‘EST EXP. (HR) 84 
LONGEST EXP. (DAY) 23 
SHORTEST EXP. (DAY) 20 
LON GEST AVG. EXPJDAY 5.24 
LEAST AVG. EXP/DAY 4.00 
Thus, the plastic products of the invention advanta 
geously, provide protective, non-irritating antiviral barriers 
for use in the work place, hospital, home and wherever 
antiviral and antibacterial barriers are required. The plastic 
product generally incorporated an anti-HIV and antibacterial 
composition. These compounds include: 
Acylclovir (Burroughs & Wellcome C0rp.)—dose range: 
200—l000 mglcmz. 
Ribavirin (ICN Pharmaceutica1s)~—dose: 
mg/cm2. 
Retrovir (AZT) (Burroughs & Wellcome C0rp.)—dose: 
200-1500 mglcmz. 
Interferon alfa-n3 (Purdue Frederick, Inc.)—dose: about 
0.5 million LU. (I.U.:International Units) 
Chlorhexidine=antirnicrobial agent (2—4%) 
PVP-Bromine 
In a preferred embodiment the anti-HIV and antibacterial 
composition is applied to the plastic product as a coating. In 
a most preferred embodiment the anti-HIV/antibacterial 
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compound is the PVP-I/N9 compound of the invention. 
The invention is not to be limited to the exact details of 
operation, or to the exact compositions, methods, proce 
dures, products or embodiments shown and described, as 
obvious modi?cations and equivalents were apparent to one 
skilled in the art. The invention is therefore to be limited 
only by the full scope which can be legally accorded to the 
appended claims. All publications cited herein, are incorpo~ 
rated herein by reference in their entirety. 
We claim: 
1. A coated paper product comprising a paper product 
coated with a high energy coprecipitate of nonoxynol oli 
gomer and polyvinyl pyrrolidone polymer and iodine, or 
nonoxynol oligomer and polyvinylpyrrolidone-iodine com 
plex (PVP-I), wherein the combined effect of the compounds 
simultaneously precipitated in said high energy coprecipi 
tate exceeds the individual effect of said compounds, and 
wherein said high energy coprecipitate has antiviral activity 
against human immunode?ciency virus-1 (HIV-1) in an 
MT~2 assay. 
2. The product of claim 1, wherein in said paper product 
is selected from the group consisting of surgical gowns, 
paper masks, paper-made bed covers, and paper liners 
utilized in hospital beds and physician’s examination tables. 
3. The product of claim 1, wherein said high energy 
coprecipitate composition is coated on said paper product by 
a coating method selected from the group consisting of 
brush coating, roll coating, pressure coating, kiss coating, 
reverse roll coating, rod coating, knife coating, print coating, 
?exo coating, gravure coating, spray coating, cold spray 
coating, hot spray coating, electrostatic spray coating, dip 
coating, and microencapsulation coating. 
4. The product of claim 3, wherein said high energy 
coprecipitate composition is sprayed onto said paper product 
in the form of a coating comprising 50—75% by weight 
antiviral composition, 6—10% polymer by weight, 9—25% by 
weight plasticizer, and 7—10% by weight ?ller. 
5. The product of claim 1, wherein said high energy 
coprecipitate composition is applied to said paper product as 
a microencapsulated coating. 
6. The product according to claim 1, wherein said copre 
cipitate is a powder. 
7. The product according to claim 6, wherein said powder 
is a ?nely divided crystalline powder. 
8. The product according to claim 1, wherein said PVP-I 
comprises about 0.09—9.4% w/w of iodine. 
9. The product according to claim 1, wherein said PVP-I 
comprises an antiviral concentration of free iodine of about 
0.03% w/v or 300 ppm complexed with PVP. 
10. The product according to claim 1, wherein said PVP-I 
comprises an effective antiviral concentration of free iodine 
of about 0.0094 w/v of iodine or 94 ppm complexed with 
PVP. . 
11. The product according to claim 1, wherein said 
nonoxynol oligomer of said coprecipitate comprises from 
about 5.8 to 11.8% w/w of nonoxynol-9 oligomer. 
12. The product according to claim 1, wherein said 
coprecipitate is present at a concentration of about 3.24 
mg/ml of PVP-I and about 0.2 mg/ml of N9 oligomer of an 
average molecular weight of 599. 
13. The product according to claim 1, wherein said 
coprecipitate is present at a concentration of about 5.8 
mg/ml PVP-I and about 0.2 mg/rnl N-9 oligomer of an 
average molecular weight of 306. 
14. The product according to claim 1 wherein said copre 
cipitate is present at a concentration of about 5 .8 ppm of N-9 
oligomer and about 940 ppm of PVP-I or 94 ppm of iodine. 
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15. The product according to claim 1, wherein said 
nonoxynol oligomer is an nonoxynol-9 oligomer with an 
average molecular weight of 599. 
16. The product according to claim 1, wherein said 
nonoxynol oligomer is nonoxynol-9 oligomer comprising 
oligomers of N-9 having a range of molecular weight of each 
oligomer from about 264 to about 1000. 
17. The product according to claim 1, wherein the percent 
of polyvinyl pyrrolidone ranges from about 88% to about 
97%. 
18. The product according to claim 1, wherein the average 
molecular weight of said polKvinyl pyrrolidone ranges from 
about 2,500 to 1,100,000. 
19. A paper product coated with an anti-HIV and anti 
bacterial composition. 
20. The product of claim 19, wherein said anti-HIV and 
antibacterial composition is applied to said paper product as 
a microencapsulated coating. 
21. The product of claim 19, wherein said anti-HIV and 
antibacterial composition is applied to said paper in the form 
of a coating with a coat weight of 2-30 g/m2 based upon a 
15 
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50—75% anti-HIV and antibacterial composition concentra 
tion in the coating. 
22. A coated plastic product comprising a plastic product 
coated with a high energy coprecipitate of nonoxynol oli 
gomer and polyvinyl pyrrolidone polymer and iodine, or 
nonoxynol oligomer and polyvinylpyrrolidone-iodine com 
plex (PVP-I), wherein the combined eifect of the compounds 
simultaneously precipitated in said high energy coprecipi~ 
tate exceeds the individual eifect of said compounds, and 
wherein said high energy coprecipitate has antiviral activity 
against human immunode?ciency virus-1 (PHV-l) in an 
MT'2 assay. 
23. The product of claim 22, wherein said plastic product 
is selected from the group consisting of gloves, plastic 
liners, and condoms. 
